Journal article

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

Jerome Galon, Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Anne Berger, Christine Lagorce, Alessandro Lugli, Inti Zlobec, Arndt Hartmann, Carlo Bifulco, Iris D Nagtegaal, Richard Palmqvist, Giuseppe V Masucci, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Michele Maio, Luigi Laghi, Fabio Grizzi, Martin Asslaber Show all

Journal of Pathology | WILEY | Published : 2014


Awarded by Qatar National Research Fund under its National Priorities Research Programme

Awarded by European Commission

Funding Acknowledgements

We acknowledge all the scientists who made contributions to the area of research reviewed here that were not cited due to space constraints. The work performed in the Laboratory of Integrative Cancer Immunology and the immunomonitoring platform of the HEGP hospital was supported by grants from the Institut National du Cancer, France (INCa), Assistance Publique-Hopitaux de Paris, the national PHRC programme IMMUCOL, the Canceropole Ile de France, INSERM, MedImmune, Qatar National Research Fund under its National Priorities Research Programme (Award No. NPRP09-1174-3-291), the European Commission (7FP, Geninca Consortium; Grant No. 202230), Cancer Research for Personalized Medicine (CARPEM) and the LabEx Immuno-oncology. The authors wish to acknowledge the following organizations for supporting the Immunoscore following the WIC meeting: Society for Immunotherapy of Cancer (SITC); the European Academy of Tumour Immunology (EATI); La Fondazione Melanoma Onlus; National Cancer Institute, USA (NCI); Biotherapy Development Association (BDA); Canadian Cancer Immunotherapy Consortium (CCIC); Cancer Immunotherapy Consortium (CIC); Cancer Research Institute (CRI); Association for Cancer Immunotherapy (CIMT); Committee for Tumour Immunology and Biotherapy (TIBT); European Society for Cancer Immunology and Immunotherapy (ESCII); Italian Network for Tumour Biotherapy (NIBIT); Japanese Association of Cancer Immunology (JACI); Nordic Centre for Development of Antitumour Vaccines (NCV-Network); Progress in Vaccination Against Cancer (PIVAC); Adoptive engineered T cell Targeting to Activate Cancer Killing (ATTACK); Tumour Vaccine and Cell Therapy Working Group (TVACT); and Institut National du Cancer, France (INCa).